Affordable Access

deepdyve-link
Publisher Website

Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance.

Authors
  • Yamada, Eijiro1
  • Lee, Ting-Wen A
  • Pessin, Jeffrey E
  • Bastie, Claire C
  • 1 Albert Einstein College of Medicine and Neuroscience, Diabetes Research and Training Center, Department of Medicine, Bronx, NY 10461, USA.
Type
Published Article
Journal
Future Medicinal Chemistry
Publisher
"Future Science, LTD"
Publication Date
Dec 01, 2010
Volume
2
Issue
12
Pages
1785–1796
Identifiers
DOI: 10.4155/fmc.10.264
PMID: 21428801
Source
Medline
License
Unknown

Abstract

Type II diabetes is characterized by elevated serum glucose levels and altered lipid metabolism due to peripheral insulin resistance and defects of insulin secretion in the pancreatic β-cells. While some cases of obesity and Type II diabetes result from genetic dysfunction, the increased worldwide incidence of these two disorders strongly suggest that the contribution of environmental factors such as sedentary lifestyles and high-calorie intake may disrupt energy balance. AMP-activated protein kinase and its upstream kinase liver kinase B1 are conserved serine/threonine kinases regulating anabolic and catabolic metabolic processes, therefore representing attractive therapeutic targets for the treatment of obesity and Type II diabetes. In this review, we will discuss the advantages of targeting the liver kinase B1/AMP-activated protein kinase pathway for the treatment of metabolic diseases.

Report this publication

Statistics

Seen <100 times